Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
JPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)